miR-150 modulates cisplatin chemosensitivity and invasiveness of muscle–invasive bladder cancer cells via targeting PDCD4 in vitro

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 1850-1857

  Lei, Y ^a   Hu, Xiheng ^a   Li, Bin ^b   Peng, Minyuan ^a   Tong, Shiyu ^a   Zu, Xiongbing ^a   Wang, Zhi ^a   Qi, Lin ^a   Chen, Minfeng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin; MicroRNAs; Urinary Bladder Neoplasms

Indexed keywords

CISPLATIN; LYMPHOCYTE ANTIGEN; MESSENGER RNA; MICRORNA; MICRORNA 150; PROGRAMMED DEATH 4 RECEPTOR; TUMOR PROMOTER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; MIRN150 MICRORNA, HUMAN; PDCD4 PROTEIN, HUMAN; PRIMER DNA; RNA BINDING PROTEIN;

ARTICLE; BLADDER CANCER CELL LINE; CHEMOSENSITIVITY; CONTROLLED STUDY; DISEASE COURSE; DNA SEQUENCE; DOWN REGULATION; DRUG SENSITIVITY; GENETIC TRANSFECTION; HEK293 CELL LINE; HUMAN; HUMAN CELL; IC50; LUCIFERASE ASSAY; MICROSCOPY; MTS ASSAY; MUSCLE INVASIVE BLADDER CANCER; PLASMID; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING; BLADDER TUMOR; DRUG EFFECTS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; BASE SEQUENCE; CELL LINE, TUMOR; CISPLATIN; DISEASE PROGRESSION; DNA PRIMERS; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; RNA-BINDING PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 84908137074     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.891340     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics. Cancer J Clin, 2013; 63: 11–30
2. Botteman MF, Pashos CL, Redaelli A et al: The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics, 2003; 21: 1315–30
3. Shah JB, McConkey DJ, Dinney CP: New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. CLin Cancer Res, 2011; 17: 2608–12
4. Stenzl A, Cowan NC, De Santis M et al: Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol, 2011; 59: 1009–18
5. Herr HW, Dotan Z, Donat SM et al: Defining optimal therapy for muscle invasive bladder cancer. J Urology, 2007; 177: 437–43
6. Svatek RS, Shariat SF, Novara G et al: Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int, 2011; 107: 898–904
7. Huang YD, Shan W, Zeng L, Wu Y: Screening of differentially expressed genes related to bladder cancer and functional analysis with DNA microarray. Asian Pac J Cancer Prev, 2013; 14: 4553–57
8. Choi W, Porten S, Kim S et al: Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell, 2014; 25: 152–65
9. Kaba M, Pirincci N, Benli E et al: Dickkopf-1 levels in Turkish patients with bladder cancer and its association with clinicopathological features. Asian Pac J Cancer Prev, 2014; 15: 381–84
10. Blower PE, Chung JH, Verducci JS et al: MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther, 2008; 7: 1–9
11. Min W, Wang B, Li J et al: The expression and significance of five types of miRNAs in breast cancer. Med Sci Monit Basic Res, 2014; 20: 97–104
12. Liu Y, Zhao J, Zhang PY et al: MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis. Med Sci Monit, 2012; 18(8): BR299–308
13. Guo Y, Ying L, Tian Y et al: miR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling. FEBS J, 2013; 280: 4531–38
14. Jiang QQ, Liu B, Yuan T: MicroRNA-16 inhibits bladder cancer proliferation by targeting Cyclin D 1. Asian Pac J Cancer Prev, 2013; 14: 4127–30
15. Han Y, Liu Y, Zhang H et al: Hsa-miR-125b suppresses bladder cancer development by down-regulating oncogene SIRT7 and oncogenic long noncoding RNA MALAT 1. FEBS Lett, 2013; 587: 3875–82
16. Zhang H, Qi F, Cao Y et al: Down-regulated microRNA-101 in bladder transitional cell carcinoma is associated with poor prognosis. Med Sci Monit, 2014; 20: 812–17
17. Wang Z: The guideline of the design and validation of MiRNA mimics. Methods Mol Biol, 2011; 676: 211–23
18. Catto JW, Alcaraz A, Bjartell AS et al: MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol, 2011; 59: 671–81
19. Zhou L, Qi X, Potashkin JA et al: MicroRNAs miR-186 and miR-150 down-regulate expression of the pro-apoptotic purinergic P2X7 receptor by activation of instability sites at the 3’-untranslated region of the gene that decrease steady-state levels of the transcript. J Biol Chem, 2008; 283: 28274–86
20. Huang S, Chen Y, Wu W et al: miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PLoS One, 2013; 8: e80707
21. Wu Q, Jin H, Yang Z et al: MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR 2. Biochem Bioph Res Commun, 2010; 392: 340–45
22. Zhang N, Wei X, Xu L: miR-150 promotes the proliferation of lung cancer cells by targeting P 53. FEBS Lett, 2013; 587: 2346–51
23. Cao M, Hou D, Liang H et al: miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1. Eur J Cancer, 2014; 50: 1013–24
24. Gu XY, Wang J, Luo YZ et al: Down-regulation of miR-150 induces cell proliferation inhibition and apoptosis in non-small-cell lung cancer by targeting BAK1 in vitro. Tumour Biol, 2014; 338–43
25. Watanabe A, Tagawa H, Yamashita J et al: The role of microRNA-150 as a tumor suppressor in malignant lymphoma. Leukemia, 2011; 25: 1324–34
26. Ma Y, Zhang P, Wang F et al: miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut, 2012; 61: 1447–53
27. Li J, Zhang Y, Liu Y et al: Microvesicle-mediated transfer of microRNA-150 from monocytes to endothelial cells promotes angiogenesis. J Biol Chem, 2013; 288: 23586–96
28. Liu Y, Zhao L, Li D et al: Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development. Protein Cell, 2013; 4: 932–41
29. Reis PP, Tomenson M, Cervigne NK et al: Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma. Mol Cancer 2010; 9: 238
30. Lankat-Buttgereit B, Goke R: The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Boil Cell, 2009; 101: 309–17
31. Wei N, Liu SS, Chan KK et al: Tumour suppressive function and modulation of programmed cell death 4 (PDCD4) in ovarian cancer. PLoS One, 2012; 7: e30311
32. Zhen Y, Liu Z, Yang H et al: Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. Cell Death Dis, 2013; L4: e872
33. Liwak U, Jordan LE, Von-Holt SD et al: Loss of PDCD4 contributes to enhanced chemoresistance in Glioblastoma multiforme through de-repression of Bcl-xL translation. Oncotarget, 2013; 4: 1365–72
34. Dou X, Wang RB, Meng XJ et al: PDCD4 as a predictor of sensitivity to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Asian Pac J Cancer Prev, 2014; 15: 825–30